Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma.

Background: The beneficial effects of immunocell therapy, using either activated lymphocytes (ALs) or dendritic cells (DCs), in the treatment of melanoma has been demonstrated. DCs are professional antigen-presenting cells that induce cytotoxic T lymphocytes against tumor cells. DC therapy may be promising when combined with ALs.